204 results about "Hepatic disorders" patented technology

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease, which is prepared from the following raw materials in parts by weight: 8 to 10 parts of ginseng, 10 to 15 parts of radix bupleuri, 10 to 15 parts of radix curcumae, 6 to 9 parts of ginger processed pinellia, 6 to 10 parts of fructus amomi, 10 to 15 parts of rhizoma atractylodis, 10 to 15 parts of poria cocos, 10 to 15 parts of semen hoveniae, 10 to 15 parts of radix rehmanniae, 8 to 10 parts of rhizoma polygoni cuspidati and 6 to 9 parts of lignum dalbergiae odoriferae. The traditional Chinese medicine composition is used for treating the metabolism-related fatty liver diseases from the aspects of liver depression, spleen deficiency and phlegm-blood stasis, starts from the core pathological chain of liver depression, spleen deficiency, phlegm-dampness and blood stasis, has the functions of soothing the liver, tonifying the spleen, resolving dampness, reducing fat and promoting blood circulation to remove meridian obstruction, and is particularly suitable for patients with liver depression, spleen deficiency and metabolism-related fatty liver diseases. Clinical tests prove that the traditional Chinese medicine composition has a good treatment effect on patients with liver depression and spleen deficiency syndrome metabolism-related fatty liver diseases, the total effective rate reaches 94% or above, and the traditional Chinese medicine composition is mild in medicine property, good in safety, stable in curative effect, not prone to relapse and suitable for being taken for a long time.

The invention belongs to the technical field of biological pharmacy, and provides an application of jonquil glucoside in preparation of a medicine for treating a metabolism-related fatty liver disease, and the application is that the jonquil glucoside is applied to preparation of the medicine for treating the metabolism-related fatty liver disease. The treatment effect of the jonquil glycoside on MASLD is evaluated by adopting a method for establishing a fatty liver model through induction of HFD high-fat, high-fructose and high-cholesterol feed. Results show that the jonquil glucoside can reduce the liver weight by inhibiting weight gain, reduce the content of TC and TG in serum, improve the conditions of liver inflammation and fat change, reduce the oxidative stress level of liver tissue and restore SIRT1 protein expression of the liver tissue to achieve the purpose of treating MASLD.

The invention discloses an application of costunolide in preparation of a medicine for treating and / or preventing a non-alcoholic fatty liver disease. It is found that costunolide can activate an Nrf2-ARE signal channel of a body, liver cell lipid metabolism abnormality is effectively improved from the molecular level, and meanwhile the pathological influence of oxidative damage on liver tissue is remarkably relieved. Experimental data show that the compound has a remarkable intervention effect on NAFLD, a scientific basis is provided for development of a novel liver disease treatment agent due to the unique dual regulation and control mechanism of the compound, particularly, the compound shows an important development prospect in the field of clinical intervention of metabolism-related liver injury, and an innovative solution is provided for NAFLD lacking a special-effect therapy at present.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention belongs to the field of traditional Chinese medicine compositions, and relates to a liver-clearing, spleen-enlivening and stasis-removing composition for treating non-alcoholic fatty liver disease, the liver-clearing, spleen-enlivening and stasis-removing composition comprises the following raw materials by weight: 10-25 g of oriental wormwood, 20-30 g of tea tree root, 20-30 g of adiantum capillus, 5-15 g of earthworm, 5-15 g of sophora flower, 5-10 g of bamboo shavings, 3-6 g of rhizoma nardostachyos, 3-6 g of lotus plumule, 6-12 g of lucid ganoderma, 10-15 g of roxburgh rose, and 5-15 g of honey-fried licorice root. The composition is used for treating the non-alcoholic fatty liver disease according to the idea of'stasis, phlegm, depression and deficiency 'and the viscera dredging theory, through a viscera connection treatment method of clearing liver and relieving depression, strengthening the spleen and clearing damp, and dredging intestines and removing stagnation, and through combination of medicines directly entering the liver channel for promoting blood circulation and dredging collaterals, breaking blood and removing stasis and medicines for caring healthy qi and strengthening the spleen and tonifying deficiency, the treatment effect is good, the effective rate is as high as 97.83%, and the curative effect is good. The traditional Chinese medicine composition is especially suitable for patients with phlegm-blood stasis type non-alcoholic fatty liver diseases.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The invention discloses a synthesis method of N-goose deoxycholyl-L-aspartic acid and application of the N-goose deoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolism-related fatty liver diseases. According to the method provided by the invention, chenodeoxycholic acid and L-dimethyl aspartate hydrochloride are taken as raw materials, and a chenodeoxycholic acid-dimethyl aspartate intermediate is synthesized, so that a target compound-N-chenodeoxycholyl-L-aspartic acid with a brand new structure is efficiently prepared. The compound shows a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as fatty degeneration, inflammation and fibrosis of the liver. The invention provides a brand new solution for major clinical challenges of insufficient curative effect, large side effect, drug withdrawal rebound and the like of the current MAFLD treatment drug, and provides a candidate compound with a wide prospect for developing a novel efficient MAFLD treatment drug.

The application provides a kind of prophylaxis and / or treatment of alcoholic liver disease, and belong to the technical field of traditional Chinese medicine.The application includes the following components by weight: turmeric extract 4.5~6 parts, radix puerariae extract 2~3 parts, raspberry extract 1~2 parts and sea buckthorn extract 0.5~1 part.The application provides a kind of prophylaxis and / or treatment of alcoholic liver disease, and belong to the technical field of traditional Chinese medicine.The application includes the following components by weight: turmeric extract 4.5~6 parts, radix puerariae extract 2~3 parts, raspberry extract 1~2 parts and sea buckthorn extract 0.5~1 part.The application provides a kind of prophylaxis and / or treatment of alcoholic liver disease, and belong to the technical field of traditional Chinese medicine.The application includes the following components by weight: turmeric extract 4.5~6 parts, radix puerariae extract 2~3 parts, raspberry extract 1~2 parts and sea buckthorn extract 0.5~1 part.

The application discloses application of aza-3 in resisting erythroleukemia, wherein the aza-3 is a compound obtained by modifying a ring of aza-3 with 3alpha-O-(Boc-proline); the application proves that the aza-3 can obviously inhibit HEL and K562 cell proliferation, reduce splenomegaly, improve anemia indexes (RBC, HGB and HCT) and splenic and hepatic pathological infiltration, and has no obvious toxic side effects on main organs such as heart, lung and kidney through in-vitro MTT experiment and a Friend virus-induced erythroleukemia mouse model.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

The application belongs to the technical field of biological medicine, and particularly relates to a nano selenium compound with liver fibrosis prevention and treatment integration function and a preparation and application thereof. The preparation method is as follows: bovine serum albumin is mixed with sodium selenite, and under the reduction of glutathione, elemental selenium is generated, BSA-Se is obtained through dialysis ultrafiltration, and then the BSA-Se is reacted with dopamine hydrochloride in a Tris-HCl buffer solution in the dark to obtain a nano drug BSA-Se@PDA (BSP). The synthesis method is simple in process, convenient in operation and good in repeatability; the BSP is high in stability, good in biocompatibility, can effectively eliminate active oxygen, inhibit the activation of liver stellate cells, and thus significantly relieve liver fibrosis; meanwhile, the BSP also shows good protection in alcoholic liver injury in the fibrosis stage, realizes the dual treatment effects of'source intervention' and 'pathological process regulation' of liver fibrosis, and provides a new nano preparation and intervention strategy for the treatment of alcoholic liver disease and liver fibrosis.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD), is a condition characterized by the accumulation of fat in the liver of individuals with no alcohol consumption, and at least one cardiometabolic risk factor (overweight / obesity, high blood pressure, high blood sugar, high triglycerides levels, low HDL-C levels). The inventors demonstrated that Rab30 silencing improve metabolic dysfunction–associated steatotic liver disease (MASLD). The present invention relates to a method for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) in a subject in need thereof comprising the administration of a therapeutically effective amount of an inhibitor of Rab30.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The composition is prepared from humifuse euphorbia herb, exocarpium benincasae, herba asari, radix platycodonis, radix sophorae flavescentis, radix rehmanniae, leech, lumbricus, radix salviae miltiorrhizae, semen pharbitidis and radix glycyrrhizae, all the raw materials are natural medicinal raw materials, and chemical synthesis anti-hepatic fibrosis components are not contained. Through the synergistic effect of multiple components, the composition inhibits the liver fibrosis process at the molecule, cell and tissue levels, improves the liver structure and function, and can be used for preparing drugs for treating liver fibrosis caused by various causes. The invention has the advantages of naturalness, safety, multiple targets and integral regulation, and is suitable for long-term intervention of chronic liver diseases.

The invention discloses polysaccharide capable of improving symptoms of alcoholic liver diseases as well as a preparation method and application of the polysaccharide, and belongs to the technical field of biological medicines. The polysaccharide capable of improving the symptoms of the alcoholic liver disease is extracted and purified from yellow water, the molecular weight of the polysaccharide is 12 kDa to 16 kDa, the polysaccharide is formed by connecting glucose units through glucosidic bonds, and the main chain glucosidic bond connection mode is [-> 4-alpha-Glcp-1-> 4-alpha-Glcp-1-> 4-alpha-Glcp-1-> 4-alpha-Glcp-1->]. The polysaccharide provided by the invention shows a clear and powerful effect of improving the alcoholic liver disease on an animal model, is derived from a natural product, is small in expected toxic and side effects, high in safety, simple in preparation method, relatively low in cost and easy to realize large-scale production, and provides a new way for preventing and treating the alcoholic liver disease.

The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.

This invention discloses a method for identifying intrahepatic cholangiocarcinoma (ICC) based on serum peptide characteristics and its application. The invention collects serum samples from three groups: individuals with ICC, those with benign liver disease, and healthy controls. Peptide characteristic peaks associated with ICC are screened, and a model is constructed using a logistic regression algorithm. This model demonstrates excellent discriminative ability on both the training and independent test sets, with AUCs reaching 0.986 and 0.963, respectively, significantly outperforming traditional tumor markers CA19-9 and CEA. The peptide characteristic peak combination and the discriminative model constructed based on it can be used for early detection of ICC, differentiation between benign and malignant cases, and screening of high-risk populations. It offers advantages such as rapid detection, standardized procedures, strong early ICC identification capability, and low false positive rate, providing a highly sensitive, specific, and widely applicable non-invasive screening tool for clinical use.

The application discloses a DNA methylation site marker for detecting hepatocellular carcinoma, a multiplex dPCR kit and a diagnostic model construction method. The DNA methylation site marker comprises cg02829688, cg13080379, cg03760839, cg10703826, cg12664119, cg16990168 and cg23371746 sites. The application designs a primer probe group for the above sites, constructs a multiplex dPCR kit of a double reaction system, realizes quantification of target DNA methylation sites, takes the methylation levels of the 7 sites as characteristic variables, adopts an XGBoost algorithm and / or an LR algorithm to construct a diagnostic model. Experimental verification shows that the model can effectively distinguish hepatocellular carcinoma patients from liver cirrhosis, chronic hepatitis B, metabolic dysfunction-related fatty liver disease patients and healthy individuals, especially shows good efficiency in auxiliary diagnosis of early hepatocellular carcinoma, and provides a new technical scheme for clinical diagnosis and screening of hepatocellular carcinoma.

The invention relates to the technical field of medicines, in particular to application of an integrin beta3 inhibitor RGDfK in preparation of a medicine for treating metabolic dysfunction related fatty liver diseases. The RGDfK provided by the invention can inhibit palmitoylation and membrane localization of CD36 in liver tissues of mice with fatty liver diseases related to metabolic dysfunction induced by high fat diet feeding, so that lipid uptake of the liver is inhibited. Experimental results show that RGDfK can improve obesity and insulin resistance of mice with metabolic dysfunction-related fatty liver diseases, can improve fat accumulation, fibrosis and inflammatory infiltration of liver tissues of the mice with fatty liver diseases, and is expected to become a new medicine for treating the metabolic dysfunction-related fatty liver diseases.

The disclosure provide compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.

Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbidities thereof. Also disclosed are compositions containing one or more of the compounds and uses of the compounds in the treatment of disorders in a subject.

The invention provides application of an SLC13A3 gene serving as a target spot in preparation of a medicine for treating metabolism-related fatty liver diseases. By constructing an MASLD cell model and an MASLD mouse model with the lesion degree from light to heavy, the expression of the SLC13A3 in the liver tissue and cell model of the metabolism-related fatty liver disease mouse is up-regulated, and the up-regulation multiple is gradually increased along with the increase of the severity of the disease. Animal experiments show that the liver specific knock-down SLC13A3 can significantly relieve weight and liver weight increase, liver fatty degeneration, liver lipid accumulation and liver function impairment accompanied by MASLD, and reduce the expression of adipogenesis genes. The invention provides a new target and a new thought for the development of drugs for treating metabolism-related fatty liver diseases.

RNAi agents, compositions, and methods for reducing patatin-like phospholipase domain-containing protein-3 (PNPLA3) levels and treating liver disease, such as NAFLD, are provided.SOLUTION: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting the expression of PNPLA3 genes. Pharmaceutical compositions comprising the PNPLA3RNAi drugs and methods of use thereof are also disclosed. The disclosed PNPLA3RNAi drugs may be conjugated to targeting ligands to facilitate delivery to cells, including hepatocytes. Delivery of the PNPLA3RNAi agent in vivo provides for inhibition of expression of the PNPLA3 gene. The RNAi agents can be used in methods of treating PNPLA3 associated diseases and disorders, including alcoholic or non-alcoholic liver disease, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic fat liver disease (NASH), liver fibrosis, and cirrhosis.SELECTED DRAWING: None

The application relates to the field of biological medicine, in particular to a medicine for improving non-alcoholic fatty liver disease. The application provides the use of ML-SA1 in the preparation of a medicine for treating non-alcoholic fatty liver disease. It is found that ML-SA1 can improve non-alcoholic fatty liver disease, specifically, can reduce the accumulation of lipid droplets in hepatocytes, reduce the weight of the liver, relieve hepatocyte vacuolization and liver tissue fibrosis, and improve the related pathological indexes of non-alcoholic fatty liver disease. It is also found that the combination of ML-SA1 and other substances can more significantly improve non-alcoholic fatty liver disease.

The invention relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases), and particularly relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases). The invention relates to an application of MASLD in a medicine, and belongs to the technical field of biological medicines. In an in-vivo experiment, a mouse MASLD model is established by adopting methionine choline deficiency diet induction, and the treatment effect of cepharanthine on MASLD is researched. Experimental results show that the cepharanthine can significantly reduce the levels of triglyceride, glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and other indexes of MASLD mice; a pathological detection result shows that cepharanthine can effectively reduce liver lipid deposition and inflammatory infiltration. In-vitro experiments prove that cepharanthine can effectively reduce the content of free fatty acid (Free Fatty Acid); fFA (Fatty Acid) induced HepG2 (HepG2) cell lipid accumulation and lipopolysaccharides (lipopolysaccharides) induced HepG2 cell lipid accumulation and lipopolysaccharides (FFA) induced HepG2 cell lipid accumulation; the THP-1 cell inflammatory response is induced by LPS (Lipopolysaccharide). In conclusion, the cepharanthine shows remarkable anti-lipid accumulation and anti-inflammatory effects in in-vivo and in-vitro experiments, can be used for preparing the medicine for preventing or treating MASLD, and has a wide application prospect.

The invention provides a small-molecule compound A3 with a good treatment effect on metabolism-related fatty liver diseases, the small-molecule compound A3 is innovatively designed and synthesized based on a pyrene skeleton, and the application of the small-molecule compound A3 in drugs for preventing and / or treating the metabolism-related fatty liver diseases. By establishing a standard in-vivo and in-vitro pharmacodynamic evaluation model, it is proved that the composition has a remarkable intervention effect on the metabolism-related fatty liver diseases. The compound improves the core pathological process of the metabolism-related fatty liver disease through multi-mechanism synergism, can effectively regulate abnormal lipid metabolism, inhibits hepatocyte vacuolation lesion and slows down excessive deposition of extracellular matrix, and shows the advantage of multi-channel treatment.

The application discloses a synthesis method of N-chenodeoxycholyl-L-aspartic acid and application of the N-chenodeoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolic associated fatty liver disease. The method provided by the application uses chenodeoxycholic acid and L-aspartic acid dimethyl ester hydrochloride as raw materials, synthesizes a chenodeoxycholic acid-aspartic acid dimethyl ester intermediate, and efficiently prepares a target compound, N-chenodeoxycholyl-L-aspartic acid, which is a novel structure, the compound exhibits a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as liver steatosis, inflammation and fibrosis. The application provides a novel solution for major clinical challenges such as insufficient treatment effect, large side effect and rebound after drug withdrawal of current MAFLD treatment medicines, and provides a candidate compound with broad prospects for developing a new high-efficiency MAFLD treatment medicine.

The invention discloses application of an Fn1-PPARbeta / delta signal channel related to a cardiac liver disease. The cardiac liver disease model is constructed according to the conditions that the liver development of young individuals is delayed due to heart injury and both adult and young individuals have serious fatty livers. In the model, the Fn1 protein level in the heart and blood is obviously increased compared with the normal level. Based on a zebra fish heart ablation means, after heart ablation injury, the heart specific knock-down Fn1 can lead to reduction of the Fn1 protein level in blood and alleviation of liver development retardation and fat deposition. Through the screening of transcriptomics, the PPARbeta / delta protein in the liver is found to be a potential downstream effect factor of Fn1. The liver specific overexpression PPARbeta / delta protein can significantly relieve abnormal phenotypes such as liver fat deposition caused by heart injury, and after the liver specific knock-down PPARbeta / delta protein, the protection effect of knock-down Fn1 on the liver disappears under the condition of heart injury. Therefore, the Fn1 protein and the PPARbeta / delta protein can be used as targets for preventing and treating the cardiac liver injury, and are used for preparing medicines for improving the cardiac liver injury, so that a new way is provided for treating the cardiac liver disease.